Sodium ascorbate
(Synonyms: 维生素C钠; Sodium ascorbate; Sodium L-ascorbate; Vitamin C sodium salt) 目录号 : GC13616
抗坏血酸钠（Sodium L-ascorbate）是一种电子供体，是一种内源性抗氧化剂。抗坏血酸钠选择性抑制 Cav3.2 通道，IC50 为 6.5 μM.抗坏血酸钠也是一种胶原蛋白沉积增强剂和弹性生成抑制剂。
Cas No.:134-03-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Animal experiment: |
A total of 40 7-week-old male Tg rats are divided into 2 groups. Twenty-seven (group 1) and 13 (group 2) rats are given a powdered MF diet with or without 5% sodium L-ascorbate, respectively. Similarly, a total of 42 7-week-old male Non-tg rats are divided into 2 groups, and 30 (group 3) and 12 (group 4) animals are given a diet with or without 5% sodium L-ascorbate, respectively. |
|
References: [1]. Hinek A, et al. Sodium L-ascorbate enhances elastic fibers deposition by fibroblasts from normal and pathologic human skin. J Dermatol Sci. 2014 Sep;75(3):173-82. |
|
L-Ascorbic acid sodium salt is a more bioavailable form of vitamin C that is an antioxidant agent.
L-Ascorbic acid sodium salt, a known enhancer of collagen deposition, has also been identified as an inhibitor of elastogenesis[1]. The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by sodium L-ascorbate (10 mM), and the effective ingredients in the medium show a relative molecular mass below 5,000[2].
Tg rats treated with sodium L-ascorbate show a higher incidence of carcinoma (29.6%), compared to those without sodium L-ascorbate (15.4%). Independent of the sodium L-ascorbate treatment, transgenic rats exhibit various kinds of malignant tumors in various organs[3]. After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the sodium L-ascorbate-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the sodium L-ascorbate-treatment is evident only with simple hyperplasias and PN hyperplasias in rats[4].
References:
[1]. Hinek A, et al. Sodium L-ascorbate enhances elastic fibers deposition by fibroblasts from normal and pathologic human skin. J Dermatol Sci. 2014 Sep;75(3):173-82.
[2]. Yang X, et al. Mouse melanoma cell line B16F10-derived conditioned medium inhibits sodium L-ascorbate-induced B16F10 cell apoptosis. Nan Fang Yi Ke Da Xue Xue Bao. 2012 Feb;32(2):146-50.
[3]. Morimura K, et al. Lack of urinary bladder carcinogenicity of sodium L-ascorbate in human c-Ha-ras proto-oncogene transgenic rats. Toxicol Pathol. 2005;33(7):764-7.
[4]. Takagi H, et al. Limited tumor-initiating activity of phenylethyl isothiocyanate by promotion with sodium L-ascorbate in a rat two-stage urinary bladder carcinogenesis model. Cancer Lett. 2005 Mar 10;219(2):147-53.
| Cas No. | 134-03-2 | SDF | |
| 别名 | 维生素C钠; Sodium ascorbate; Sodium L-ascorbate; Vitamin C sodium salt | ||
| 化学名 | sodium (R)-2-((S)-1,2-dihydroxyethyl)-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate | ||
| Canonical SMILES | O=C1C(O)=C([O-])[C@@H]([C@@H](O)CO)O1.[Na+] | ||
| 分子式 | C6H7NaO6 | 分子量 | 198.11 |
| 溶解度 | ≥ 9.1mg/mL in Water | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.0477 mL | 25.2385 mL | 50.477 mL |
| 5 mM | 1.0095 mL | 5.0477 mL | 10.0954 mL |
| 10 mM | 0.5048 mL | 2.5239 mL | 5.0477 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。